Related Experiment Video
Updated: Dec 26, 2025
Diffusion Tensor Magnetic Resonance Imaging in the Analysis of Neurodegenerative Diseases
Published on: July 28, 2013
What Else Can We Use in The Discrimination of Activated MS Plaques in Addition to Diffusion MRI?
1Department of Radiology, Ataturk University School of Medicine, Erzurum, Turkey.
Abstract:
Acute respiratory distress syndrome is characterized by dyspnea at presentation, tachypnea on physical examination, findings of bilateral infiltration in chest radiography, refractory hypoxia, and high mortality. Although the main treatment approach is to address the underlying disease, there are also pharmacological and nonpharmacological options for supportive treatment. There is currently no pharmacological agent with proven efficacy in this syndrome, and many drugs are being studied for this purpose. One of these is the endothelin receptor antagonist bosentan.
Insights
Acute respiratory distress syndrome (ARDS) requires supportive care as no drug is proven effective. The endothelin receptor antagonist bosentan is being studied as a potential treatment for ARDS.
Area of Science:
- Pulmonology
- Critical Care Medicine
- Pharmacology
Background:
- Acute respiratory distress syndrome (ARDS) presents with severe respiratory failure.
- Current ARDS management focuses on supportive care and addressing underlying causes.
- No specific pharmacological treatment has demonstrated proven efficacy in ARDS.
Purpose of the Study:
- To investigate the potential of endothelin receptor antagonists as a treatment for ARDS.
- To evaluate bosentan, an endothelin receptor antagonist, for its efficacy in ARDS.
Main Methods:
- Review of current treatment strategies for ARDS.
- Exploration of pharmacological agents under investigation for ARDS.
- Focus on the role of endothelin receptor antagonists, specifically bosentan.
Main Results:
- ARDS is characterized by refractory hypoxia and high mortality.
- Supportive treatments are crucial but limited in pharmacological options.
- Bosentan is identified as a drug candidate under investigation for ARDS.
Conclusions:
- There is an unmet need for effective pharmacological treatments for ARDS.
- Endothelin receptor antagonists like bosentan represent a potential therapeutic avenue.
- Further research is warranted to establish the efficacy of bosentan in ARDS management.
